Coloplast: Turnaround Is Underway, But Upside Is Limited

Coloplast remains a long-term 'Buy' but with limited short-term upside as shares approach intrinsic value. CLPBF's revised mid-term guidance now targets 5–7% organic growth and EBIT margins in the mid-20% range, reflecting a more cautious outlook. Full-year results were impacted by a DKK 3.0B impairment, yet adjusted EPS grew 39.1% and free cash flow rose 16.4% year-over-year.